Purified Cortrophin Gel Now Available for Certain Chronic Autoimmune Disorders
The product is available through a network of specialty pharmacies and distributors.
Rheumatoid Arthritis
Yusimry, a Humira Biosimilar Product, Gets FDA Approval
The approval was based on a comprehensive data package demonstrating that Yusimry was highly similar to the reference product, Humira.
Rinvoq Labeling Updated to Include Class Warnings Related to JAK Inhibitors
The update follows the FDA’s Drug Safety Communication, which was based on a completed review of a large randomized safety clinical trial evaluating tofacitinib in patients with rheumatoid arthritis.
Most Immunosuppressive Meds Not Tied to Worse COVID-19 Outcomes
Except for rituximab, no increased risk seen for in-hospital death or mechanical ventilation for those on long-term immunosuppressive therapy
ACR: Cycling JAK Inhibitors Feasible for Difficult-to-Treat RA
One-year outcomes similar for cycling JAK inhibitors versus switching to a biologic drug
FDA Approves Cortrophin Gel for Certain Chronic Autoimmune Disorders
Cortrophin Gel is a purified adrenocorticotropic hormone.
First Interchangeable Biosimilar to Humira Gets FDA Approval
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
MPR Weekly Dose Podcast Episode 92
This week we have news on pediatric influenza vaccine guidance; Moderna submit data for their COVID-19 booster dose; There’s new FDA warnings for some JAK inhibitors; Trudhesa nasal spray is approved; And the FDA places a clinical hold on a gene therapy for phenylketonuria.
mRNA COVID-19 Vaccines Immunogenic in Immunosuppressed Patients
Titers of anti-S IgG lower for patients with chronic inflammatory disease receiving glucocorticoids or B-cell depletion therapy
FDA: New Warnings and Limitations Set for Certain JAK Inhibitors
The revisions are based on a completed review of a large randomized safety clinical trial, which included 4362 patients with rheumatoid arthritis.
